• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of clinical pharmacology =: Journal canadien de pharmacologie clinique >Reducing costs and improving hypertension management
【24h】

Reducing costs and improving hypertension management

机译：降低成本并改善高血压管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To quantify the cost-savings that could be realized by switching patients from two separate agents, ACE inhibitor/ARB and thiazide diuretic, to a fixed dose combination product. Methods CompuScript and Longitudinal Rx (LRx) Insights data from IMS Health Canada for Oct 2006-Sept 2007 was used. From the LRx data, the proportion of patients taking both ACE inhibitors/ARBs and thiazide diuretics as two separate products was calculated to determine how many would qualify for a combination product. From the CompuScript data, the total number of prescriptions for ACE inhibitors and ARBs and the actual average dollar value per prescription for thiazide diuretics, ACE inhibitors, ARBs, and ACE inhibitor/ARB with thiazide diuretic combination products was used to determine the potential cost savings of switching from two separate drugs to a combination product. As a sensitivity analysis, the proportion of patients receiving two separate products who could be switched to a combination product was varied from 60-100%. This analysis was done for Alberta and Canada. Results The conversion of ACE inhibitor/ARB and thiazide diuretic as two separate agents to a combination product could potentially result in a yearly cost-savings of $27 to $45 million for Canada ($1.1 to $1.9 million for Alberta), based on 60-100% conversion to a combination product. Conclusions The present analysis has shown that a simple intervention of converting patients receiving separate ACE inhibitor/ARB and thiazide diuretic prescriptions to a single combination product prescription will produce substantial cost-savings for the health care system and simplify the medication regimen for patients.
机译：目的量化将患者从两种单独的药物（ACE抑制剂/ ARB和噻嗪类利尿药）转换为固定剂量组合产品可节省的费用。方法使用了来自IMS Health Canada的2006年10月至2007年9月的CompuScript和纵向Rx（LRx）见解数据。根据LRx数​​据，计算出同时服用ACE抑制剂/ ARBs和噻嗪类利尿剂作为两种单独产品的患者比例，以确定有多少人可以使用组合产品。从CompuScript数据中，使用ACE抑制剂和ARB的处方总数以及噻嗪类利尿剂，ACE抑制剂，ARB和ACE抑制剂/ ARB与噻嗪类利尿剂联合产品的每个处方的实际平均美元价值来确定潜在的成本节省从两种单独的药物转换为组合产品的过程。作为敏感性分析，接受两种单独产品并可以转换为组合产品的患者比例在60％至100％之间变化。这项分析是针对艾伯塔省和加拿大进行的。结果将ACE抑制剂/ ARB和噻嗪类利尿剂作为两种单独的药物转换为一种联合产品，根据60-100％的比例，加拿大每年可能节省27至4,500万元（艾伯塔省1.1至190万元）的成本。转换为组合产品。结论本分析表明，将接受单独ACE抑制剂/ ARB和噻嗪类利尿剂处方的患者转换为单一组合产品处方的简单干预将为卫生保健系统节省大量成本，并简化患者的用药方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号